Side-effects of intravenous cyclophosphamide pulse therapy

Lupus

Volumn 6, Issue 3, 1997, Pages 254-257

  Martin, F ^a   Lauwerys, B ^a   Lefebvre C ^a   Devogelaer, J P ^a   Houssiau, F A ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cyclophosphamide; Lupus; Pulse; Side effects; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID;

ALOPECIA; ARTICLE; AUTOIMMUNITY; DRUG THERAPY; ETIOLOGY; HYPOPHARYNX CARCINOMA; INFECTION; LUNG SQUAMOUS CELL CARCINOMA; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; PULSE GENERATOR; SKIN CARCINOMA; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 0030969723     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600307     Document Type: Article

References (16)

1. Scott DGI, Salmon M, Bacon PA. Pulsed cyclophosphamide and steroids in systemic vasculitis. Clin Rheumatol 1987; 6: 132 (abstract).
2. Fort JG, Abruzzo JL. Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis Rheum 1988; 31: 1194-1198
3. Boumpas DT et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
4. Austin HA et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619
5. Houssiau FA, D'Cruz DP, Haga HJ, Hughes GRV. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991; 1: 31-35.
6. Valeri A et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-78.
7. Belmont HM, Storch M, Buyon J, Abraham S. New York University/Hospital for joint diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 104-108.
8. McCune WJ et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423-1431
9. De Bandt M et al. Traitement du lupus èrythèmateux aigu disséminé par cyclophosphamide en perfusions intraveineuses. Intèrêts et limites. Ann Med Interne 1994; 145: 75-87.
10. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methyl-prednisolone in the treatment of systemic rheumatoid vasculitis Am J Med 1984; 76: 377-384.
11. Killian JM, Bressler RB, Armstrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 1988; 45 27-30.
12. De Vita S, Neri R, Bombardieri S Cyclophosphamide pulses in the treatment of rheumatic diseases. an update. Clin Exp Rheumatol 1991; 9: 179-193.
13. Reiner A, Gemsheimer T, Shchter S. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85: 351-358.
14. Haga H-J, D'Cruz D, Asherson R, Hughes GRV. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992; 51: 885-888.
15. Radis CD et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study. Arthritis Rheum 1995; 38: 1120-1127.
16. Buckner CD et al. High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response and the effects of stored autologous marrow. Cancer 1972; 29: 357-364.